Get the Stockscreener App
163.36
9.06%
13.57
After Hours:
163.36
Charles River Laboratories International Inc stock is traded at $163.36, with a volume of 1.88M.
It is up +9.06% in the last 24 hours and up +10.79% over the past month.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
See More
Previous Close:
$149.79
Open:
$157.42
24h Volume:
1.88M
Relative Volume:
1.68
Market Cap:
$8.02B
Revenue:
$4.06B
Net Income/Loss:
$413.08M
P/E Ratio:
20.39
EPS:
8.01
Net Cash Flow:
$560.48M
1W Performance:
+5.79%
1M Performance:
+10.79%
6M Performance:
-2.89%
1Y Performance:
-28.23%
1-Day Range:
$155.48
$167.83
1-Week Range:
$146.26
$167.83
52-Week Range:
$91.86
$254.15
Charles River Laboratories International Inc Stock (CRL) Company Profile
Name
Charles River Laboratories International Inc
Sector
Industry
Phone
781-222-6000
Address
251 BALLARDVALE ST, WILMINGTON, MA
Compare CRL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
163.36 | 7.58B | 4.06B | 413.08M | 560.48M | 8.01 |
|
TMO
Thermo Fisher Scientific Inc
|
427.62 | 157.79B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
189.91 | 138.02B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
532.00 | 42.36B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
116.19 | 32.08B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
187.38 | 27.28B | 15.50B | 1.33B | 2.16B | 7.34 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Upgrade | Citigroup | Neutral → Buy |
| May-23-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| May-14-25 | Upgrade | TD Cowen | Hold → Buy |
| May-08-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-21-25 | Downgrade | Goldman | Buy → Neutral |
| Mar-04-25 | Upgrade | Citigroup | Sell → Neutral |
| Mar-03-25 | Upgrade | Redburn Atlantic | Sell → Neutral |
| Jan-22-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-17-25 | Downgrade | UBS | Buy → Neutral |
| Nov-18-24 | Downgrade | CLSA | Hold → Underperform |
| Nov-07-24 | Upgrade | CLSA | Underperform → Hold |
| Oct-23-24 | Initiated | CLSA | Underperform |
| Oct-14-24 | Initiated | Redburn Atlantic | Sell |
| Oct-07-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-02-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-01-24 | Downgrade | Citigroup | Neutral → Sell |
| Aug-08-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-08-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-28-24 | Downgrade | Argus | Buy → Hold |
| Jun-07-24 | Initiated | Mizuho | Neutral |
| Jun-06-24 | Initiated | Goldman | Buy |
| Feb-15-24 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-13-23 | Initiated | TD Cowen | Market Perform |
| Jul-10-23 | Downgrade | Citigroup | Buy → Neutral |
| Feb-23-23 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-12-23 | Downgrade | Jefferies | Buy → Hold |
| Sep-30-22 | Upgrade | Jefferies | Hold → Buy |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Aug-04-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-24-22 | Initiated | Guggenheim | Neutral |
| Apr-25-22 | Downgrade | Jefferies | Buy → Hold |
| Apr-07-22 | Initiated | Stephens | Overweight |
| Feb-17-22 | Reiterated | BofA Securities | Buy |
| Feb-17-22 | Upgrade | Citigroup | Neutral → Buy |
| Feb-17-22 | Reiterated | Deutsche Bank | Buy |
| Feb-17-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-17-22 | Reiterated | UBS | Buy |
| Aug-05-21 | Resumed | Credit Suisse | Neutral |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Sep-10-20 | Upgrade | Jefferies | Hold → Buy |
| Jul-01-20 | Upgrade | BofA Securities | Neutral → Buy |
| May-13-20 | Upgrade | UBS | Neutral → Buy |
| Apr-21-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-27-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-02-20 | Initiated | Deutsche Bank | Buy |
| Feb-18-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-10-20 | Upgrade | Goldman | Neutral → Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-18-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-10-19 | Initiated | SVB Leerink | Outperform |
| Apr-30-19 | Resumed | Evercore ISI | Outperform |
| Dec-14-18 | Initiated | Deutsche Bank | Buy |
| Oct-09-18 | Initiated | UBS | Neutral |
| Aug-23-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-17-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-15-18 | Upgrade | KeyBanc Capital Mkts | Sector Weight → Overweight |
| Feb-14-18 | Upgrade | SunTrust | Hold → Buy |
View All
Charles River Laboratories International Inc Stock (CRL) Latest News
What analysts say about Charles River Laboratories International Inc. stockOutstanding capital returns - jammulinksnews.com
What drives Charles River Laboratories International Inc. stock priceMarket-crushing stock picks - Autocar Professional
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
Charles River Labs Stock Rises on Plasmid DNA Deal with Ellys TeamNews and Statistics - IndexBox
Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Why Are Charles River Laboratories (CRL) Shares Soaring Today - Yahoo Finance
Is Charles River Laboratories International Inc. a good long term investmentRapid-fire capital growth - jammulinksnews.com
Gene Therapy Breakthrough: Charles River Helps Develop First Treatment for Ultra-Rare Disease in Just 13 Months - Stock Titan
Here's What to Expect From Charles River Laboratories' Next Earnings Report - MSN
Charles River Laboratories International Inc. Stock Analysis and ForecastHigh-velocity capital appreciation - jammulinksnews.com
How Charles River Laboratories International Inc. stock reacts to Fed policy changesReal Chart Play - beatles.ru
Is it Prudent to Retain Charles River Stock in Your Portfolio Now? - MSN
Agree To Purchase Charles River Laboratories International At $150, Earn 21.4% Annualized Using Options - Nasdaq
Pharma Contract Research Organization (CRO) Services Market to Cross USD 36.66 Billion in 2025, Expanding at a CAGR of 10.04% - GlobeNewswire Inc.
Here's What To Expect From Charles River Laboratories' Next Earnings Report - Barchart.com
Is Charles River Laboratories International (NYSE:CRL) Using Too Much Debt? - simplywall.st
Why Charles River Laboratories International Inc. stock attracts strong analyst attentionHigh Potential Stock Ideas - beatles.ru
CFRA downgrades Charles River Labs (CRL) to a Hold - The Globe and Mail
Gordon Reid discusses Charles River Laboratories Intl. Inc - BNN Bloomberg
Charles River Laboratories Schedules Second-Quarter 2025 Earnings Release and Conference Call - BioSpace
Charles River Laboratories International (CRL) is Expected to Gain as Industry Growth Resumes - Insider Monkey
U.S. Physical Therapy, Evolent Health, Charles River Laboratories, Moderna, and Intuitive Surgical Shares Are Falling, What You Need To Know - FinancialContent
Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Charles River Labs (CRL) - The Globe and Mail
Evercore ISI Adjusts PT on Charles River Laboratories International to $180 From $170 - MarketScreener
This Microsoft Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga
Charles River Labs stock rating upgraded by Citi on DSA growth prospects - Investing.com Canada
Cathie Wood Agrees Circle IPO Is 'Crypto's ChatGPT Moment' — Warns Institutions That Ignoring The AI-Crypto Combo 'Just Isn't An Option'Charles River (NYSE:CRL) - Benzinga
Charles River Laboratories International Inc. Stock Outperforms Competitors On Strong Trading Day - 富途牛牛
5 Revealing Analyst Questions From Charles River Laboratories’s Q1 Earnings Call - Yahoo Finance
Is Charles River Laboratories Stock Underperforming the S&P 500? - MSN
Charles River Laboratories: FDA Regulation And High Debt Are Signs Of Headwinds - Seeking Alpha
Charles River Laboratories: Riding the AI Drug Discovery Wave Amid Regulatory Crosscurrents - AInvest
Shareholders in Charles River Laboratories International (NYSE:CRL) are in the red if they invested three years ago - simplywall.st
Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Charles River Announces Endosafe® Cartridge Recycling Program, Strengthening Sustainability Commitment | CRL Stock News - GuruFocus
Charles River Announces Endosafe® Cartridge Recycling Program, Strengthening Sustainability Commitment - Business Wire
Do Wall Street Analysts Like Charles River Laboratories Stock? - MSN
Global Viral Inactivation Market | Solvent Detergent & - openPR.com
Charles River falls after projecting 2025 revenue drop - MSN
Charles River Laboratories International Inc Stock (CRL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.06%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):